Patients with CKD display a significantly higher risk of cardiovascular and thromboembolic
complications, with around half of patients with advanced CKD ultimately dying of …

Delaying disease progression and reducing the risk of mortality are key goals in the
treatment of chronic kidney disease (CKD). New drug classes to augment renin–angiotensin …

Background: The efficacy and safety of aspirin for primary prevention of cardiovascular
disease (CVD) remain debatable. Objectives: The purpose of this study was to examine the …

Dyslipidemia is an emerging mechanism in microvascular complications in T2D. Elucidating
the molecular pathomechanisms may pinpoint potential lipid-centric treatments …

More than a century after its synthesis, daily aspirin, given at a low dose, is a milestone
treatment for the secondary prevention of cardiovascular disease (CVD). Its role in primary …

Aims The efficacy and safety of aspirin for primary cardiovascular disease (CVD) prevention
is controversial. The aim of this study was to investigate the efficacy and safety of aspirin in …

Background The effects of aspirin in adults without atherosclerotic cardiovascular disease
(ASCVD), stratified by statin use across different ASCVD risks, remain uncertain. Objectives …

Aims Cardiovascular disease (CVD) is the major cause of morbidity and mortality in
individuals with chronic kidney disease (CKD). This study assessed the risks and benefits of …

Background Chronic microinflammation contributes to the progression of chronic kidney
disease (CKD). Aspirin (ASA) has been used to treat inflammation for centuries. The effects …

Aim Chronic kidney disease is associated with increased risk of cardiovascular diseases
(CVD). This meta-analysis aims to evaluate the efficacy and safety of aspirin administered …